Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, and Liechti ME (2020). Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 45, 462–471.

Luethi D, and Liechti ME (2020). Designer drugs: mechanism of action and adverse effects. Arch Toxicol 94, 1085–1133.

Holze F, Duthaler U, Vizeli P, Muller F, Borgwardt S, and Liechti ME (2019). Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol 85, 1474–1483.

Luethi D, Hoener MC, Krahenbuhl S, Liechti ME, and Duthaler U (2019). Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochem Pharmacol 164, 129–138.

Rickli A, Liakoni E, Hoener MC, and Liechti ME (2018). Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol 175, 532–543.